FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804021909> ?p ?o ?g. }

• W2804021909 endingPage "291.e6" @default.
• W2804021909 startingPage "276" @default.
• W2804021909 abstract "BackgroundGermline gain-of function (GOF) mutations in PIK3CD, encoding the catalytic p110δ subunit of phosphoinositide 3-kinase (PI3K), result in hyperactivation of the PI3K–AKT–mechanistic target of rapamycin pathway and underlie a novel inborn error of immunity. Affected subjects exhibit perturbed humoral and cellular immunity, manifesting as recurrent infections, autoimmunity, hepatosplenomegaly, uncontrolled EBV and/or cytomegalovirus infection, and increased incidence of B-cell lymphoproliferation, lymphoma, or both. Mechanisms underlying disease pathogenesis remain unknown.ObjectiveUnderstanding the cellular and molecular mechanisms underpinning inefficient surveillance of EBV-infected B cells is required to understand disease in patients with PIK3CD GOF mutations, identify key molecules required for cell-mediated immunity against EBV, and develop immunotherapeutic interventions for the treatment of this and other EBV-opathies.MethodsWe studied the consequences of PIK3CD GOF mutations on the generation, differentiation, and function of CD8+ T cells and natural killer (NK) cells, which are implicated in host defense against infection with herpesviruses, including EBV.ResultsPIK3CD GOF total and EBV-specific CD8+ T cells were skewed toward an effector phenotype, with exaggerated expression of markers associated with premature immunosenescence/exhaustion and increased susceptibility to reactivation-induced cell death. These findings were recapitulated in a novel mouse model of PI3K GOF mutations. NK cells in patients with PIK3CD GOF mutations also exhibited perturbed expression of differentiation-associated molecules. Both CD8+ T and NK cells had reduced capacity to kill EBV-infected B cells. PIK3CD GOF B cells had increased expression of CD48, programmed death ligand 1/2, and CD70.ConclusionsPIK3CD GOF mutations aberrantly induce exhaustion, senescence, or both and impair cytotoxicity of CD8+ T and NK cells. These defects might contribute to clinical features of affected subjects, such as impaired immunity to herpesviruses and tumor surveillance. Germline gain-of function (GOF) mutations in PIK3CD, encoding the catalytic p110δ subunit of phosphoinositide 3-kinase (PI3K), result in hyperactivation of the PI3K–AKT–mechanistic target of rapamycin pathway and underlie a novel inborn error of immunity. Affected subjects exhibit perturbed humoral and cellular immunity, manifesting as recurrent infections, autoimmunity, hepatosplenomegaly, uncontrolled EBV and/or cytomegalovirus infection, and increased incidence of B-cell lymphoproliferation, lymphoma, or both. Mechanisms underlying disease pathogenesis remain unknown. Understanding the cellular and molecular mechanisms underpinning inefficient surveillance of EBV-infected B cells is required to understand disease in patients with PIK3CD GOF mutations, identify key molecules required for cell-mediated immunity against EBV, and develop immunotherapeutic interventions for the treatment of this and other EBV-opathies. We studied the consequences of PIK3CD GOF mutations on the generation, differentiation, and function of CD8+ T cells and natural killer (NK) cells, which are implicated in host defense against infection with herpesviruses, including EBV. PIK3CD GOF total and EBV-specific CD8+ T cells were skewed toward an effector phenotype, with exaggerated expression of markers associated with premature immunosenescence/exhaustion and increased susceptibility to reactivation-induced cell death. These findings were recapitulated in a novel mouse model of PI3K GOF mutations. NK cells in patients with PIK3CD GOF mutations also exhibited perturbed expression of differentiation-associated molecules. Both CD8+ T and NK cells had reduced capacity to kill EBV-infected B cells. PIK3CD GOF B cells had increased expression of CD48, programmed death ligand 1/2, and CD70. PIK3CD GOF mutations aberrantly induce exhaustion, senescence, or both and impair cytotoxicity of CD8+ T and NK cells. These defects might contribute to clinical features of affected subjects, such as impaired immunity to herpesviruses and tumor surveillance." @default.
• W2804021909 created "2018-06-01" @default.
• W2804021909 creator A5005206087 @default.
• W2804021909 creator A5015128003 @default.
• W2804021909 creator A5016237829 @default.
• W2804021909 creator A5017924520 @default.
• W2804021909 creator A5020110150 @default.
• W2804021909 creator A5031536047 @default.
• W2804021909 creator A5033045876 @default.
• W2804021909 creator A5035492315 @default.
• W2804021909 creator A5037185138 @default.
• W2804021909 creator A5040384200 @default.
• W2804021909 creator A5040661117 @default.
• W2804021909 creator A5046316209 @default.
• W2804021909 creator A5048616194 @default.
• W2804021909 creator A5056552919 @default.
• W2804021909 creator A5058891305 @default.
• W2804021909 creator A5065257722 @default.
• W2804021909 creator A5065346505 @default.
• W2804021909 creator A5077913296 @default.
• W2804021909 date "2019-01-01" @default.
• W2804021909 modified "2023-10-15" @default.
• W2804021909 title "Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity" @default.
• W2804021909 cites W1512205565 @default.
• W2804021909 cites W1560450744 @default.
• W2804021909 cites W1612160402 @default.
• W2804021909 cites W1910012553 @default.
• W2804021909 cites W1914062369 @default.
• W2804021909 cites W1914351900 @default.
• W2804021909 cites W1965845165 @default.
• W2804021909 cites W1975753196 @default.
• W2804021909 cites W1978436252 @default.
• W2804021909 cites W1981480494 @default.
• W2804021909 cites W1982323892 @default.
• W2804021909 cites W1987853079 @default.
• W2804021909 cites W1990423632 @default.
• W2804021909 cites W1991276398 @default.
• W2804021909 cites W1996890984 @default.
• W2804021909 cites W2000961821 @default.
• W2804021909 cites W2014522512 @default.
• W2804021909 cites W2015035059 @default.
• W2804021909 cites W2015278246 @default.
• W2804021909 cites W2016804396 @default.
• W2804021909 cites W2017190378 @default.
• W2804021909 cites W2035852466 @default.
• W2804021909 cites W2039260444 @default.
• W2804021909 cites W2040851810 @default.
• W2804021909 cites W2052090039 @default.
• W2804021909 cites W2052931854 @default.
• W2804021909 cites W2055630249 @default.
• W2804021909 cites W2056285250 @default.
• W2804021909 cites W2058001723 @default.
• W2804021909 cites W2058150655 @default.
• W2804021909 cites W2059473808 @default.
• W2804021909 cites W2066425902 @default.
• W2804021909 cites W2072765132 @default.
• W2804021909 cites W2076111197 @default.
• W2804021909 cites W2081420986 @default.
• W2804021909 cites W2086014112 @default.
• W2804021909 cites W2102364227 @default.
• W2804021909 cites W2110232771 @default.
• W2804021909 cites W2115091768 @default.
• W2804021909 cites W2119146367 @default.
• W2804021909 cites W2121698141 @default.
• W2804021909 cites W2123273309 @default.
• W2804021909 cites W2124711116 @default.
• W2804021909 cites W2135511012 @default.
• W2804021909 cites W2136614697 @default.
• W2804021909 cites W2144796561 @default.
• W2804021909 cites W2158966732 @default.
• W2804021909 cites W2163577434 @default.
• W2804021909 cites W2512972788 @default.
• W2804021909 cites W2513184125 @default.
• W2804021909 cites W2529584177 @default.
• W2804021909 cites W2560303109 @default.
• W2804021909 cites W2562506237 @default.
• W2804021909 cites W2567426572 @default.
• W2804021909 cites W2592935721 @default.
• W2804021909 cites W2605742765 @default.
• W2804021909 cites W2623997875 @default.
• W2804021909 cites W2760003250 @default.
• W2804021909 cites W2761652334 @default.
• W2804021909 cites W2783767400 @default.
• W2804021909 cites W2790663567 @default.
• W2804021909 doi "https://doi.org/10.1016/j.jaci.2018.04.030" @default.
• W2804021909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29800648" @default.
• W2804021909 hasPublicationYear "2019" @default.
• W2804021909 type Work @default.
• W2804021909 sameAs 2804021909 @default.
• W2804021909 citedByCount "60" @default.
• W2804021909 countsByYear W28040219092018 @default.
• W2804021909 countsByYear W28040219092019 @default.
• W2804021909 countsByYear W28040219092020 @default.
• W2804021909 countsByYear W28040219092021 @default.
• W2804021909 countsByYear W28040219092022 @default.
• W2804021909 countsByYear W28040219092023 @default.
• W2804021909 crossrefType "journal-article" @default.
• W2804021909 hasAuthorship W2804021909A5005206087 @default.

• next